# KdT Ventures

> KdT Ventures is a VC fund in Austin backing Biotechnology and Health Care. See 94 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Austin, United States
- Total investments: 94
- Last investment: Mar 2026
- Lead investor: 9%
- Fund size: $80M
- Last fund: Jan 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/kdt-ventures
- Website: https://www.kdtvc.com

KdT Ventures is an early-stage venture capital firm that invests in startups in the data, engineering, and biology sector, as well as healthcare technology systems, pharmaceuticals, biotechnology, agriculture, chemicals, gases, and life sciences. The firm was founded in 2017 in Austin, Texas by Cain McClary.

## Contacts

5 contacts available for KdT Ventures. Shizune tracks 6 team members at KdT Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kdt-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.6M–$13M |
| Series A | $9M–$70M |
| Series B | $25M–$175M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 33 | 35% |
| Health Care | 29 | 31% |
| Medical | 20 | 21% |
| Artificial Intelligence | 12 | 13% |
| Life Science | 9 | 10% |

59 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 40 | 43% |
| Series A | 27 | 29% |
| Series B | 6 | 6% |
| Convertible Note | 2 | 2% |
| Venture - Series Unknown | 2 | 2% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 52 | 55% |
| India | 1 | 1% |
| Canada | 1 | 1% |
| Israel | 1 | 1% |
| Germany | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew McClary | Founder and Managing Partner | 7 | https://shizune.co/investors/profile/cain-mcclary |
| Phil Grayeski | Principal | 0 | https://shizune.co/investors/profile/phil-grayeski |
| Ally Gudeman | Head of Operations | 0 | https://shizune.co/investors/profile/ally-gudeman |
| Isaac Stoner | Advisor & LP | 0 | https://shizune.co/investors/profile/isaac-b-stoner |
| Mack Healy | Managing Partner | 1 | https://shizune.co/investors/profile/mack-healy |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tacit Therapeutics | Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California. | $19M | Series A | Mar 09, 2026 |  |
| Skeletalis | Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis. | $8M | Seed | Nov 17, 2025 |  |
| Zag Bio | Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. | $80M | Series A | Oct 28, 2025 |  |
| Faeth Therapeutics | Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy.The company was founded totranslate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians. | $25M | Series A | Oct 20, 2025 |  |
| PHNX Materials | PHNX Materials is a manufacturing company that specializes in turning waste into essential materials and reduce carbon emissions. | $2.5M | Seed | Apr 21, 2025 |  |
| Character Biosciences | Biopharmaceutical research and development company that's an affiliate of Clover Health | $93M | Series B | Mar 25, 2025 |  |
| Montara Therapeutics | Montara Therapeutics is a biotechnology company. | $20M | Seed | Mar 13, 2025 |  |
| Reverb Therapeutics | Reverb Therapeutics engages in the development of treatments for cancer and other diseases. | $12M | Seed | Feb 19, 2025 |  |
| MacroCycle Technologies | MacroCycle is developing a technology to curb the usage of fossil fuel derived plastic through a circular, sustainable and zero-carbon plastic upcycling process. The company's proprietary process based on the synthesis of cyclic macromolecules enables us to produce virgin-grade recycled PET from plastic waste at lower energy use thantraditional processes. | $6.5M | Seed | Feb 06, 2025 |  |
| Shiprocket | Shiprocket is an eCommerce shipping platform that enables cost-effective shipping for direct-to-consumer retailers. Its platform employs a machine-learning-based data engine that recommends proper courier service for a business and chooses a courier company, prints shipping labels, and tracks orders from a single panel that enables businesses tomanage their shipping and returns simply and effectively.The company was founded in 2017 and is headquartered in New Delhi, India. | $25.6M | Series E | Dec 26, 2024 |  |

10 of 94 investments shown.

## Co-investors
- [Digitalis Ventures](https://shizune.co/investors/profile/digitalis-ventures) — VC Fund, 15 deals together
- [Cantos](https://shizune.co/investors/profile/cantos-ventures) — VC Fund, 9 deals together
- [Fifty Years](https://shizune.co/investors/profile/fifty-years) — VC Fund, 8 deals together
- [Pillar VC](https://shizune.co/investors/profile/pillar-companies-2) — VC Fund, 6 deals together
- [Refactor](https://shizune.co/investors/profile/refactor-capital) — VC Fund, 6 deals together
- [Two Bear Capital](https://shizune.co/investors/profile/two-bear-capital) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Health Care Investors in United States](https://shizune.co/investors/health-care-investors-united-states)
- [Health Care VC Funds in United States](https://shizune.co/investors/health-care-vc-funds-united-states)
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)

## FAQ

### What does KdT Ventures invest in?

KdT Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 94 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is KdT Ventures's check size?

KdT Ventures typically joins rounds of $2.6M–$13M at Seed, $9M–$70M at Series A and $25M–$175M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds KdT Ventures participates in.

### How do I contact KdT Ventures?

Public channels for KdT Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at KdT Ventures?

The team at KdT Ventures includes Andrew McClary (Founder and Managing Partner), Phil Grayeski (Principal) and Ally Gudeman (Head of Operations), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co